- In April 2024, Eli Lilly and Company announced the launch of a new monoclonal antibody therapy targeting nerve growth factor (NGF) to manage moderate to severe osteoarthritis pain. This innovative therapy, developed in collaboration with a leading biotechnology firm, aims to provide long-lasting pain relief without the adverse effects commonly associated with NSAIDs and opioids, positioning Lilly at the forefront of next-generation osteoarthritis treatment
- In March 2024, Pfizer Inc. initiated Phase III clinical trials for its investigational disease-modifying osteoarthritis drug (DMOAD), designed to slow cartilage degeneration in patients with knee osteoarthritis. This development aligns with the growing global focus on regenerative approaches and personalized medicine in chronic joint conditions
- In February 2024, Johnson & Johnson’s Janssen Pharmaceuticals division received FDA Fast Track designation for its small-molecule inhibitor aimed at halting osteoarthritis progression. The drug targets inflammatory pathways implicated in cartilage breakdown, marking a major advancement in modifying disease progression beyond symptomatic relief
- In January 2024, Sanofi and Regeneron expanded their collaboration to evaluate the potential of Dupilumab in treating osteoarthritis-related inflammation and pain. Preliminary studies demonstrated promising results in reducing joint stiffness and improving mobility, opening new therapeutic possibilities for patients unresponsive to traditional treatments
- In December 2023, GlaxoSmithKline (GSK) launched a novel topical analgesic gel incorporating nanotechnology for enhanced penetration and sustained pain relief. This product, developed for over-the-counter use, is tailored to improve the quality of life for patients with early-stage osteoarthritis and has seen strong market uptake across Europe and Asia-Pacific
